Bruker Q3 Revenue Rises 1.6%; Non-GAAP EPS Increases 24.4%

What happened

Bruker reported third-quarter 2026 revenue of $874.0 million, up 1.6% from a year earlier, and non-GAAP diluted earnings per share of $0.56, up 24.4%. It recorded a $174.5 million goodwill impairment charge and a GAAP diluted loss per share of $0.81, while reaffirming its full-year outlook.

Confirmed

Global impact / market context

The impairment charge turned reported earnings into a GAAP loss even as adjusted earnings rose. Bruker reaffirmed its outlook, but organic revenue growth of 0.7% indicates limited sales expansion so far, which could constrain the pace at which revenue supports operating costs and investment.

Analyst inference

Bruker’s scientific instruments unit recorded bookings and backlog up mid-single digits year to date, while the company reported modest organic revenue growth. If those orders convert into deliveries, they could support future sales; the article does not specify when or how much they will contribute.

Analyst inference

What to watch

1. Compare upcoming results with Bruker’s reaffirmed FY2026 organic revenue growth guidance of 1% to 2% and non-GAAP EPS guidance of $2.10 to $2.15. Confirmed
2. Bruker expects foreign currency to be neutral to reported revenue under its updated assumptions; watch whether exchange-rate movements change the contribution from sales abroad. Confirmed
3. Watch whether scientific-instrument bookings and backlog growth convert into reported sales; delays could leave revenue growth modest and weaken the expected support for future earnings. Analyst inference

Evidence

• Original source link unavailable